Effect of the botanical formula LCS101 on the anti-cancer effects of radiation therapy
Background and purpose
The botanical formula LCS101 has been shown in clinical research to reduce chemotherapy-induced toxicities. In pre-clinical research, the formula demonstrated selective anti-cancer effects, in part as a result of radical oxygen species (ROS) activity of the botanical components. The present study examined the interaction between LCS101 and radiation therapy on cancer cell lines.
Incremental doses of LCS101 were added to breast adenocarcinoma (MCF7), prostate (DU145), transitional cell bladder carcinoma (T24), pancreatic epithelioid carcinoma (PANC-1), and osteosarcoma (U20S) cell lines 4 h after single-dose irradiation (range 0.5–4 Gy). Cell viability was tested using sulforhodamine B (SRB) assay after 1 week, with ROS activity examined using 1 mM of the ROS scavenger sodium pyruvate (ROS scavenger), testing cell viability with an SRB assay.
The addition of LCS101 to MCF7 (breast) and DU-145 (prostate) cancer cell lines resulted in a dose-dependent increase in the antiproliferative effects of radiation treatment. The addition of pyruvate inhibited radiation-induced cell death in all of the cell lines treated with LCS101.
The addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.
KeywordsBotanical formula LCS101 Cancer Radiation therapy Radical oxygen species
We are grateful for the Adelis Foundation for their ongoing support of our research.
All of the authors participated in the conception and design of the research, and preparation of the study article.
No funding was provided for this study.
Compliance with ethical standards
Conflict of interest
Dr. Yair Maimon is a shareholder of LifeBiotics Ltd. No conflict of interest exists for any of the other authors.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Hall E (2000) Repair of radiation damage and the dose-rate effect. In: John J-R, sutton P, Marino D (eds) Radiobiology for the radiologist, 5th edn. Lippincott Williams and Wilkins, Philadelphia, 67–90Google Scholar
- Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH (2012) Letter to the editor regarding “A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer” by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197–1202). Oncologist 17(5):740–741 (author reply 742–3) CrossRefPubMedPubMedCentralGoogle Scholar
- National Cancer Institute: Antioxidants and Cancer Prevention (2018) https://www.cancer.gov/about-cancer/causes-prevention/risk/diet/antioxidants-fact-sheet. Accessed Aug 2018
- Rachmut IH, Samuels N, Melnick SJ, Ramachandran C, Sharabi Y, Pavlovsky A, Maimon Y, Shoham J (2013) Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment. Onco Targets Ther 24:6:437–445Google Scholar
- Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F, Samuels N, Shoham J, Merimsky O (2011) A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist 16(9):1197–1202CrossRefPubMedPubMedCentralGoogle Scholar